Overjet Caries Assist-Pediatric
Overjet, Inc • Radiology • 03/04/2024
Device Purpose
Overjet Caries Assist-Pediatric (OCA-Ped) is an AI-powered software utilizing a machine learning model to analyze dental radiographs, functioning as a computer-assisted detection tool to help clinicians identify and segment carious lesions on bitewing and periapical images in children aged 4-11. Clinical studies demonstrate that OCA-Ped improves dentists' caries detection sensitivity, serving as an adjunctive diagnostic aid rather than a replacement for professional clinical judgment.
Summary
Overjet Caries Assist-Pediatric (OCA-Ped) is a software-only medical device designed as a radiological, automated, concurrent-read, computer-assisted detection (CADe) tool. Its primary purpose is to assist dental clinicians in detecting and segmenting dental caries on bitewing and periapical radiographs for pediatric patients aged 4-11 years, who may have primary, permanent, or mixed dentition. The system operates using a three-layer architecture: a Network Layer to ingest radiographic images, a Decision Layer where a machine learning model analyzes these images to predict carious lesions, and a Presentation Layer that displays these predictions as adjustable polygon annotations on a dashboard. OCA-Ped is intended as an adjunctive tool to provide additional diagnostic information and is not meant to replace a dentist's comprehensive review or clinical judgment, which incorporates patient history and in vivo clinical assessments. The performance of OCA-Ped was evaluated through multi-reader multi-case (MRMC) studies and standalone testing. In the MRMC study involving 20 dentists and 636 images, clinicians assisted by OCA-Ped demonstrated a statistically significant 7.5% improvement in caries detection, measured by the area under the weighted Alternative Free-Response Receiver Operating Characteristic (wAFROC) curve, compared to unassisted reading. This was accompanied by an 11.8% increase in average tooth-level sensitivity, although there was a slight 1.1% decrease in average tooth-level specificity. Standalone performance testing on 1190 images showed a tooth-level sensitivity of 83.9%, a specificity of 97.5%, and a mean Dice coefficient of 79.0% for lesion segmentation, with performance varying slightly across different X-ray sensor brands. These results indicate the device enhances clinicians' ability to identify caries in the specified pediatric population.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the OCA-Ped software's machine learning model differentiate between various stages or severities of carious lesions in pediatric dentition, and does its performance vary accordingly?; Given the slight decrease in specificity (1.1%) with OCA-Ped assistance in the MRMC study, what are the potential clinical implications of false positives, particularly in a pediatric population where conservative treatment is often prioritized?; What were the specific criteria used by the three general dentists to establish the consensus reference standard for caries detection in both the MRMC and standalone performance studies?; How does the device's performance (sensitivity, specificity, Dice coefficient) vary across different types of primary versus permanent teeth within the 4-11 age range, and are there more granular performance data across different radiographic sensor brands beyond the listed sensitivities?; Were there any specific types or locations of caries (e.g., interproximal, occlusal, early enamel lesions vs. more advanced dentinal caries) where the OCA-Ped demonstrated notably higher or lower accuracy compared to unaided visual inspection by dentists?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Qualifies as a cyber device under §524B (post-Dec 2023, networked)
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM, SaaSBOM, HBOM detected in AI-generated device summary.
• SBOM not mentioned in AI-generated device summary. Under §524B (effective Oct 2023), cyber devices must provide a SBOM.
• Cybersecurity risk assessment not referenced in AI-generated device summary. FDA cybersecurity guidance (2023) expects this for cyber devices.
• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.
• Not detected in AI-generated device summary: SBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly